Patent: 10,137,193
✉ Email this page to a colleague
Summary for Patent: 10,137,193
Title: | Methods for treating or preventing asthma by administering an IL-4R antagonist |
Abstract: | The invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods featured in the invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody. |
Inventor(s): | Pirozzi; Gianluca (Berkeley Heights, NJ), Skobieranda; Franck (Flourtown, PA), Li; Yongtao (Springfield, NJ), Graham; Neil (Croton-on-Hudson, NY), Weinstein; Steven P. (Hartsdale, NY) |
Assignee: | Sanofi Biotechnology (FR) Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) |
Application Number: | 14/627,728 |
Patent Claims: | see list of patent claims |
Details for Patent 10,137,193
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Regeneron Pharmaceuticals, Inc. | DUPIXENT | dupilumab | Injection | 761055 | 03/28/2017 | ⤷ Try a Trial | 2034-09-15 |
Regeneron Pharmaceuticals, Inc. | DUPIXENT | dupilumab | Injection | 761055 | 10/19/2018 | ⤷ Try a Trial | 2034-09-15 |
Regeneron Pharmaceuticals, Inc. | DUPIXENT | dupilumab | Injection | 761055 | 06/18/2020 | ⤷ Try a Trial | 2034-09-15 |
Regeneron Pharmaceuticals, Inc. | DUPIXENT | dupilumab | Injection | 761055 | 06/14/2021 | ⤷ Try a Trial | 2034-09-15 |
Regeneron Pharmaceuticals, Inc. | DUPIXENT | dupilumab | Injection | 761055 | 10/20/2021 | ⤷ Try a Trial | 2034-09-15 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |